SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences trades higher on the BSE

11 Mar 2024 Evaluate

Zydus Lifesciences is currently trading at Rs. 1007.05, up by 30.25 points or 3.10% from its previous closing of Rs. 976.80 on the BSE.

The scrip opened at Rs. 986.60 and has touched a high and low of Rs. 1015.70 and Rs. 980.00 respectively. So far 44133 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1015.70 on 11-Mar-2024 and a 52 week low of Rs. 461.50 on 13-Mar-2023.

Last one week high and low of the scrip stood at Rs. 1015.70 and Rs. 920.50 respectively. The current market cap of the company is Rs. 102131.40 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.03% and 6.99% respectively.

Zydus Lifesciences has received the Establishment Inspection Report (EIR) report from the USFDA for the inspection conducted at the API Ahmedabad facility. The company had earlier received Post Application Action Letter from the USFDA for the same inspection confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. This facility underwent an inspection from December 14 to 22, 2023 and has been classified as Voluntary Action Indicated (VAI).

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

936.35 -6.20 (-0.66%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×